Floatz logo

Daunomycin

Acute Myeloid Leukemia By FAB Classification

Wake Forest University Health SciencesSmall moleculePhase 3Active
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Acute Myeloid Leukemia By FAB Classification cohort.

Asset / SponsorPhaseRating
Idarubicin
University of Nebraska
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Roswell Park Cancer Institute
Phase 3BB
Valspodar
National Cancer Institute (NCI)
Phase 3BB
Azacitidine
guomei
Phase 2BB

View all 49 →

Same molecule, other indications

Daunomycin is also rated in:

acute monocytic leukemiaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BBB
Indicative · Phase 3
77 / 100
View asset →
acute myeloblastic leukemia without maturationActive
BBB
Indicative · Phase 3
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →